الفهرس | Only 14 pages are availabe for public view |
Abstract Background: Hodgkin’s lymphoma (HL) is a highly curable malignant disease. Risk adapted therapy for children with HL is directed toward high survival, minimal toxicity and optimal quality of life. Purpose: To estimate overall survival (OS) and Event free survival (EFS) of Hodgkin’s lymphoma pediatric patients treated at National Cancer Institute (NCI), Cairo University, Egypt. Methods: This is a retrospective study that included all newly diagnosed Classic Hodgkin’s lymphoma pediatric patients treated at National Cancer Institute (NCI), Cairo University (CU) between January 2016 till December 2018. Results: In 69 eligible patients, median age was 8 years (range 3 – 17 years). Male to female ratio of 4.7:1. Cervical lymphadenopathy was the commonest presentation (43%). Most cases had nodular sclerosis histologic subtype (33 cases; 47.8%). Elevates ESR (>50) was found in 18%, 42% had ≥3 LN affection, 11% had bulky mediastinal disease, B-symptoms was present in 34% of patients. The majority of patients received chemotherapy alone 47 patients (68%), while 22 patients (31%) received combined modality treatment (CMT). 3y OS & EFS in patients receiving CMT was 95.5% & 87.6% vs 89.9% & 83.3% in patients receiving chemotherapy alone (P= 0.72 & 0.909). Patients with Interim negative had a 3y OS & EFS (94.7% & 84.8%) vs (74.1% & 74.1%) in patients with interim positive (P= 0.068 & 0.351). Patients with negative interim PET who received CMT had 3y OS & EFS of (100% & 88.2%) vs (95% & 90%) in patients receiving chemotherapy alone (P= 0.35 & 0.719). At the end of the study, EFS and OS was (83% and 91.9%) respectively. Nine cases had positive interim PET and had a significantly lower EFS and OS than the cases with negative interim PET (74.1% and 74.1%) vs (84.8% and 94.7%) Conclusion: Age >15 years, B-symptoms, ≥3 involved LN groups, and stage were significant pretreatment predictors of outcome, Risk and response adaptive treatment is the standard of care for treating pediatric patients with Hodgkin lymphoma, PET/CT is the standard tool for diagnosis and response assessment in HL. |